Curie Capital

What Curie Capital does

Curie Capital is a Netherlands-based venture capital firm founded in 2018 and headquartered in Amstelveen, specializing exclusively in early-stage life sciences investments. The firm invests at Seed and Series A stages in biotechnology, pharmaceutical, and medical technology companies developing therapeutics, diagnostics, and class IIb/III medical devices, with disclosed portfolio companies spanning targeted protein degradation (Laigo Bio's SureTACs platform), multifunctional antibody oncology (Avidicure's AVC-Boosters), targeted thrombolytics (TargED Biopharmaceuticals' VhH-based enzyme delivery platform), NET-targeting antibodies for autoimmune disease (Citryll's CIT-013), surgical marker navigation (Sirius Medical's Pintuition system, MDR CE-marked), small-molecule immuno-oncology (Flindr Therapeutics), and senescence therapeutics (Cleara Biotech). The portfolio originates primarily from Dutch and Belgian academic translational centers, including UMC Utrecht, the Netherlands Cancer Institute, VIB, and the Oncode Institute.

Curie Capital operates four fund vehicles (Curie Capital Holding and Curie Capital I, II, III, IV), all SFDR Article 6 compliant and exclusively life sciences-focused, with the current Curie Capital 3 fund structured under RVO seed capital regulations limiting investments to Dutch-headquartered companies that have not previously raised more than €3.5 million. The firm typically acts as lead investor and actively syndicates with experienced co-investors including BioGeneration Ventures, EQT Life Sciences, Forbion, Johnson & Johnson Innovation–JJDC, Novartis Venture Fund, Kurma Partners, Biovance Capital, Andera Partners, and others.

The firm generates returns through equity investments in early-stage life sciences companies, earning proceeds via portfolio exits through acquisition, IPO, or secondary transactions, supplemented by standard VC management fees and carried interest on its fund vehicles. Its distribution channels for deploying capital are direct equity investments, while portfolio companies reach end markets through pharma commercialization partnerships, medical device direct sales, and distributor networks (e.g., Sirius Medical's exclusive distribution agreement with Mammotome in the U.S., Germany, Italy, and Poland).

Name

Curie Capital

Legal name

Curie Capital

Website

https://curiecapital.nl

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

1–10 employees

Short description

Curie Capital is a Netherlands-based life sciences venture capital firm founded in 2018 that invests at Seed and Series A stages in biotechnology, pharmaceutical, and medical technology companies developing therapeutics, diagnostics, and class IIb/III medical devices across Europe.

Ownership category

akta.pro rank

Product category

Life Sciences Venture Capital

NAICS

Other Financial Investment Activities (5239), Portfolio Management and Investment Advice (523940)

SIC

Investment Advice (6282)

akta.pro primary industry

Institutional Capital Introduction (LP/Family Office/Endowment Matching) (FSAEALAI)

Keywords

• Venture capital
• Life sciences investing
• Seed stage funding
• Biotech venture capital
• Medical device investment

Headquarters

HQ city

Netherlands

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

1. Venture Capital Fund Management: Curie Capital generates returns through equity investments in early-stage life sciences companies. The firm invests its own capital alongside syndicate partners and earns returns through portfolio company exits via acquisition, IPO, or secondary transactions.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Curie Capital is a Netherlands-based venture capital firm that invests its own capital and limited-partner capital in early-stage (Seed and Series A) Biotechnology, Pharmaceutical and Medical Technology companies focused on therapeutics, diagnostics, and class IIb and III medical devices. The firm typically acts as lead investor, syndicates rounds with experienced co-investors, and provides portfolio companies with hands-on operational support, management guidance, and access to an extensive industry network.

Product overview

Curie Capital is a Life Sciences venture capital firm that provides investment services rather than traditional products. The firm invests in early-stage Biotechnology, Pharmaceutical, and Medical Technology companies through its seed and Series A funds (Curie Capital I, II, III, and IV). Their portfolio companies develop therapeutics, diagnostics, and medical devices addressing unmet medical needs across oncology, immunology, cardiovascular diseases, and surgical navigation.

Differentiator

Problem solved

Functional benefit

Products and services

• Curie Capital Holding
• Curie Capital I
• Curie Capital II
• Curie Capital III
• Curie Capital IV
• Seed and Series A equity investment with lead-investor syndication and hands-on portfolio support

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Ten partnerships are on record, tiered exclusive distributor, research partner, research grant partner, clinical research partner, founding partner, technology origin and origin institution.

• Mammotomeexclusive distributorChannel Partner/ Reseller/ DistributorSirius Medical and Mammotome entered an exclusive distribution agreement for the Pintuition® System in the United States and Germany (February 2025), later expanded to Italy and Poland (September 2025). Mammotome leverages its extensive sales network to commercialize the Pintuition system.
• VIB (Flanders Institute for Biotechnology)research partnerStrategic or Co-development PartnerFlindr Therapeutics partnered with VIB (Flanders' leading life sciences research institute) and the lab of Professor Rudi Beyaert at VIB-UGent Center for Inflammation Research to leverage deep expertise in immunology and RNF31 biology for development of animal cancer models.
• ReumaNederland (Dutch Arthritis Society)research grant partnerStrategic or Co-development PartnerReumaNederland awarded a grant to Citryll and leading rheumatology centers (Amsterdam UMC, Leiden UMC, Radboud UMC, Reade) for the SONNET project to study NETosis biology and its correlation to disease status and treatment outcomes in rheumatoid arthritis.
• Amsterdam University Medical Centre (AUMC)clinical research partnerStrategic or Co-development PartnerProf. Dr. Sander Tas from Amsterdam UMC participates in the SONNET research collaboration with Citryll and ReumaNederland to study NETosis in rheumatoid arthritis.
• Leiden University Medical Centre (LUMC)clinical research partnerStrategic or Co-development PartnerDr. Joannes Reijers from LUMC participates in the SONNET research collaboration with Citryll to study NETosis in rheumatoid arthritis.
• Radboud University Medical Centre (RUMC)clinical research partnerStrategic or Co-development PartnerDr. Rogier Thurlings from RUMC participates in the SONNET research collaboration and serves as Lead Investigator of Citryll's Citydream Phase IIa trial in rheumatoid arthritis.
• Readeclinical research partnerStrategic or Co-development PartnerProf. Dr. Mike Nurmohamed from Reade participates in the SONNET research collaboration with Citryll to study NETosis in rheumatoid arthritis.
• Oncode Institutefounding partnerStrategic or Co-development PartnerLaigo Bio was founded by the Oncode Institute together with the Oncode Bridge Fund and Argobio Studio. Prof Madelon Maurice's laboratory at UMC Utrecht developed the SureTACs™ technology platform.
• UMC Utrecht (University Medical Center Utrecht)technology originStrategic or Co-development PartnerLaigo Bio's SureTACs™ platform was developed by Prof Madelon Maurice's laboratory at UMC Utrecht. TargED is a spin-off of UMC Utrecht.
• Netherlands Cancer Instituteorigin institutionStrategic or Co-development PartnerSirius Medical has its roots deeply embedded in the Netherlands Cancer Institute (NKI). The ImmunoGram Drug Discovery Engine used by Flindr Therapeutics evolved from seminal work in the laboratories of the NKI and the Oncode Institute.

Scale indicators11 records

Recent moves1 record

Expansion highlights5 records

Direct peers

• BioGeneration Ventures (BGV): Dutch life sciences venture capital firm focused on early-stage biotech and medtech. Directly comparable because it operates in the same geography, similar fund size, and is a repeat co-lead investor in Curie Capital portfolio companies (e.g., TargED, Avidicure).
• Kurma Partners: European life sciences VC firm with a focus on early-stage biotech, operating Argobio Studio as a company-creation platform. Directly comparable as a co-lead investor in Laigo Bio's seed and TargED's Series A2, and a frequent syndicate partner in the same Dutch/European biotech deals.
• V-Bio Ventures: Belgian life sciences VC firm investing in early-stage therapeutics and platform technologies. Comparable as the lead investor of Flindr Therapeutics' Series A and a co-investor in Avidicure — operating at the same stage and check size in the same Benelux ecosystem.
• Biovance Capital: European life sciences VC firm focused on early-stage biotech investments. Directly comparable as the co-lead of Laigo Bio's €17M seed alongside Kurma Partners, competing for similar Dutch/European seed-stage biotech deals.
• Hadean Ventures: Nordic-European life sciences VC firm investing in therapeutics and medical technology. Comparable as a participant in TargED's Series A syndicate and as a peer early-stage European biotech investor in the same geography and stage bracket.
• Inkef Capital: Dutch-based VC firm with a life sciences focus alongside technology investments. Comparable as a participant in TargED's Series A2 syndicate and as a Dutch peer competing for life sciences deal flow.
• Sunstone Life Science Ventures: European early-stage life sciences VC firm based in Denmark. Comparable as a participant in TargED's Series A syndicate and as a peer investor in seed/Series A European biotech and medtech companies.

Broad incumbents

• Forbion: Pan-European life sciences VC firm managing multiple large funds across the biotech and medtech spectrum. Comparable as a co-lead investor in Citryll's Series B and as a broader incumbent that competes with Curie Capital for syndicate positions on Dutch/European biotech rounds.
• EQT Life Sciences: Large European life sciences investor (part of EQT Group) writing both early- and growth-stage biotech checks. Comparable as the lead investor of Avidicure's $50M seed and a competing capital source for Dutch early-stage life sciences companies.
• Andera Partners: European private equity firm with a dedicated life sciences branch (formerly Edmond de Rothschild). Comparable as a repeat investor in TargED's Series A and A2 extensions and as a broader French/European life sciences fund manager.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/curie-capital

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments14 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Curie Capital